Published in Lab Business Week, November 5th, 2006
The data indicated that AeroLEF provided benefit compared to placebo, however the difference between the treatment arm and placebo arm had not yet achieved the significance level predefined in the study protocol and, therefore, the study will continue as planned to enroll the original target of 99 randomized patients.
"This preliminary review indicates...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.